Sun Sep 15 16:36:47 UTC 2024: ## Regeneron Pharmaceuticals Sees Increased Institutional Investment: CoreCap Advisors Enters the Game

**New York, NY (September 15, 2024)** – CoreCap Advisors LLC has taken a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the firm’s recent SEC filing. The institutional investor acquired 313 shares of the biopharmaceutical company, valued at approximately $329,000.

This move follows a trend of other institutional investors adjusting their holdings in Regeneron. Several hedge funds and institutional investors boosted their stakes in the company, including Gilbert & Cook Inc., Envestnet Portfolio Solutions Inc., Avantax Advisory Services Inc., Haverford Trust Co, and Meridian Wealth Management LLC.

Hedge funds and institutional investors now own 83.31% of Regeneron’s stock, reflecting a strong confidence in the company’s future prospects.

Regeneron’s stock opened at $1,153.35 on Friday, with a 50-day moving average of $1,124.22 and a 200-day moving average of $1,026.18. The company boasts a market cap of $127.15 billion and a P/E ratio of 34.07.

Recent research reports have been largely positive, with analysts from TD Cowen, Morgan Stanley, StockNews.com, Argus, and Guggenheim offering “buy” or “strong buy” ratings. The consensus rating for Regeneron is currently “Moderate Buy,” with an average target price of $1,109.70.

Regeneron’s focus on discovering and developing medicines for various diseases has earned the company a reputation for innovation. Its flagship product, EYLEA, treats wet age-related macular degeneration and other eye conditions.

This surge in institutional investment underscores the growing confidence in Regeneron’s ability to deliver on its promise of groundbreaking medical advancements.

Read More